In struggling Vallon, NKT-focused GRI Bio spots opportunity to jump onto Nasdaq

Eight months after the failure of Vallon Pharmaceuticals’ only clinical asset sent the biotech on a hunt for an escape route, the floundering company’s story has come to an end thanks to an acquisition by GRI Bio.